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OBJECTIVES The purpose of this study was to evaluate the prevalence and diagnostic utility of cardiac
troponin I to identify patients with right ventricular (RV) dysfunction in pulmonary
embolism.
BACKGROUND Right ventricular overload resulting from elevated pulmonary resistance is a common finding
in major pulmonary embolism. However, biochemical markers to assess the degree of RV
dysfunction have not been evaluated so far.
METHODS In this prospective, double-blind study we included 36 study patients diagnosed as having
acute pulmonary embolism.
RESULTS Among the whole study population, 14 patients (39%) had positive troponin I tests. Ten of
16 patients (62.5%) with RV dilatation had increased serum troponin I levels, while only 4 of
14 patients (28.6%) with elevated troponin I values had a normal RV diameter as assessed by
echocardiography, indicating that positive troponin I tests were significantly associated with
RV dilatation (p 5 0.009). Patients with positive troponin I tests had significantly more
segmental defects in ventilation/perfusion lung scans than patients with normal serum
troponin I (p 5 0.0002).
CONCLUSIONS Our data demonstrate that more than one-third of patients clinically diagnosed as having
pulmonary embolism presented with elevated serum troponin I concentrations. Troponin I
tests helped to identify patients with RV dilatation who had significantly more segmental
defects in lung scans. Thus, troponin I assays are useful to detect minor myocardial damage
in pulmonary embolism. (J Am Coll Cardiol 2000;36:1632–6) © 2000 by the American
College of Cardiology
Pulmonary embolism still remains a major cause of cardio-
vascular death, despite new therapeutic strategies to prevent
hemodynamic deterioration, such as thrombolysis or pul-
monary embolectomy. Thromboembolic events are difficult
to distinguish from other cardiovascular and respiratory
syndromes due to nonspecific symptoms and diagnostic
signs, suggesting that pulmonary embolism is often unde-
tected and treated with inappropriate therapeutic proce-
dures (1–6). Although the exact incidence of pulmonary
embolism is unknown due to its variable clinical presenta-
tion and degree of hemodynamic instability, this disorder is
usually considered to have a remarkable morbidity (2–
4,6,7). In order to commence aggressive treatment without
delay, it is a great challenge for treating physicians to
diagnose this common disorder promptly. The high mor-
tality of major acute thromboembolic events is generally
accepted to be associated with sudden right ventricular (RV)
dysfunction (2–4,6,7). As a result of pulmonary arterial
obstruction and elevated pulmonary vascular resistance, the
mechanical afterload in the RV increases, and the tension in
the ventricular wall rises to pathological levels, leading to
the acute dilation of the RV. Right ventricular dilation and
hypokinesis in the presence of normal or hypotensive
arterial pressure may lead to myocardial ischemia.
Cardiac-specific isoforms of troponin have been reported
to be sensitive biochemical markers for minor myocardial
damage (8–17). Troponin I and troponin T function
together as essential components of the contractile appara-
tus in striated muscle and are released in the blood flow as
a result of myocardial necrosis (8,18). Numerous studies
have demonstrated that measurements of cardiac troponins
are useful for the objective risk assessment in patients
presenting with unstable angina pectoris and myocardial
infarction (8–15,17). However, the diagnostic value of
troponin measurements in pulmonary embolism is unknown
because, so far, no systematic investigation has evaluated the
prevalence of elevated serum concentrations that result from
acute RV overload. Thus, the aim of this study was to test
the hypothesis that a recently developed high-sensitive assay
for the detection of cardiac troponin I in serum samples
could identify patients with severe embolic episodes.
METHODS
Patient population. This study was conducted over an
eight-month period from January 1999 at the University
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Hospital Go¨ttingen. The subjects of this prospective, mono-
center trial consisted of patients finally diagnosed as suffering
from acute pulmonary embolism. Patients with symptoms of
suspected pulmonary embolism, such as arterial hypotension,
tachypnea/dyspnea, syncope, arterial hypoxemia or cardiogenic
shock, were included in the study if at least one of the following
criteria was met: a positive diagnostic pulmonary angiogram, a
lung scan indicating intermediate or high probability for the
diagnosis of pulmonary embolism, precapillary pulmonary
hypertension as assessed by right heart catheterization, or
echocardiographic signs of RV dilatation with normal left
ventricular systolic function. Patients were not included in the
study if the clinical symptoms were judged to be caused by
either sepsis, hypovolemia, or acute respiratory failure. Partic-
ular efforts were undertaken not to include patients suffering
from coronary heart disease (CHD). Thus, patients admitted
with angina pectoris were strictly excluded, as were all patients
with electrocardiographic findings suggesting ischemic heart
attack.
Study patients were recruited from either the emergency
department, both medical and surgical wards, or the inten-
sive care units. Data from the history, physical examination
and electrocardiograms were obtained from the medical
records. No attempt was made by the investigators to
influence the process of diagnosing pulmonary embolism in
patients presenting with symptoms clinically suggestive of
thromboembolic episodes. Treating physicians were com-
pletely blinded to the serum levels of troponin I. Patients
remained under the medical care of the physicians, who
decided the further therapeutic management. Written in-
formed consent to participate in the study was obtained
from all patients after the nature of the investigation had
been fully explained. The study protocol was approved by
the Human Ethics Committee at the university where this
investigation was carried out.
Blood samples and laboratory methods. Blood samples
were obtained at enrollment, immediately after pulmonary
embolism was diagnosed. Samples were centrifuged, and
aliquots were frozen at 270°C for subsequent measure-
ments of cardiac troponin I and D-dimers. The measure-
ments of serum markers were performed by laboratory
personnel blinded to the clinical data. Cardiac troponin I
concentrations were measured using the ACS:180 cTnI
assay from Bayer Diagnostics (Fernwald, Germany). This is
a two-site sandwich immunoassay based on an automated
chemiluminescence detection system. The assay uses con-
stant amounts of polyclonal goat anti–troponin I antibody
labeled with acridinium ester and a combination of different
monoclonal mouse anti–troponin I antibodies covalently
coupled with paramagnetic particles. According to the
manufacturer, the assay measures troponin I concentrations
up to 50 mg/L, with a minimum detectable concentration of
0.15 mg/L. All incubations, pipetting and measurement
steps were performed automatically on the ACS:180 ana-
lyzer. The complete procedure requires approximately
10 min to obtain the test result. Blood samples that were
analyzed for troponin I were also examined for D-dimers
using an enzyme-linked immunosorbent assay from Roche
Diagnostics, Mannheim (Germany). For the measurements
of creatine kinase (CK), N-acetylcysteine-activated assays
from Roche Diagnostics were performed on a Hitachi 917
analyzer. An immuno-inhibition assay based on the pres-
ence of antibodies to the CK-M subunit was used to
determine the concentrations of the CK-MB isoenzyme.
Investigations. All consecutive patients in whom the diag-
nosis of pulmonary embolism was made underwent echocar-
diographic examination. The transthoracic echocardiography
was standardized using the apical, parasternal, subcostal and,
occasionally, the suprasternal approaches. The echocardio-
graphic criteria of major embolic events included pulmonary
hypertension, RV afterload stress and tricuspidal regurgitation.
“Right ventricular dilation” was defined as a diastolic diameter
.30 mm. Pathological changes in serial 12-lead electrocardio-
grams were recorded such as ST-depressions, right precordial
T-wave inversions, complete right bundle branch blocks
(RBBBs), atrial fibrillation, S-waves in lead I and aVL and
right axis deviation. The blood pressure in the pulmonary
artery was determined in a minority of study patients using a
Swan-Ganz catheter. Ventilation/perfusion lung scans were
performed in all patients presenting with symptoms suggestive
of pulmonary embolism. For ventilation studies, xenon 133
was used; and for perfusion studies, technetium 99m macro-
aggregated to albumin was used. A “positive lung scan” was
defined as a ventilation-perfusion mismatch showing segmen-
tal and lobar filling defects.
Statistical analyses. All results are expressed as means 6
standard deviations. The differences between the two tro-
ponin groups with the diagnostic parameters were analyzed
using Pearson chi-square tests for categorial variables. Stu-
dent t tests for continuous variables were calculated to
determine the statistical significance of the partial pressure
of O2 and the number of segmental defects in lung scans in
predicting troponin elevations. A p value ,0.05 was con-
sidered to be statistically significant.
RESULTS
Clinical findings at diagnosis. A total of 36 patients
diagnosed as suffering from pulmonary embolism were
included in the study. Baseline characteristics of the patient
population are summarized in Table 1. The study popula-
tion consisted of 23 women (64%); the mean age was
62.7 6 15.8 years. All patients except three complained of
dyspnea at enrollment (92%). Thirty-three individuals
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(92%) presented with syncope, of whom 12 also had clinical
signs of breathlessness. Pleuritic chest pain was recorded in
13 patients (36%); all of these subjects also had dyspnea. In
12 patients (33%) pulmonary embolism developed in the
immediate postoperative period. Six patients (17%) were
suffering from malignant tumors. In 17 subjects (47%)
deep-vein thromboses of the lower limbs were diagnosed
using B-mode and/or Doppler ultrasonographic or phlebo-
graphic studies. Circulatory collapse with assisted ventila-
tion was observed in two patients (6%). Three patients (8%)
demonstrated signs of cardiogenic shock as judged by the
need for catecholamine infusions.
The electrocardiographic changes in the study population
were as follows: 3 patients (8%) with S-waves in lead I and
aVL, 3 patients (8%) with right axis deviation, 4 patients
(11%) with atrial fibrillation, 6 subjects (17%) with RBBB
and 10 subjects (28%) with right precordial T-wave inver-
sion. Right ventricular dilatation as determined by echocar-
diographic examination was observed in 16 individuals
(44%). Lung scanning was performed in 36 patients, of
whom 29 (81%) had positive results. Twenty-three patients
(64%) underwent catheterization of the right heart. Among
these, 16 subjects (70%) had pulmonary hypertension as
defined by a systolic blood pressure .25 mm Hg.
Data from troponin I measurements. In the total study
population troponin I tests were positive in 14 patients
(39%) and were below the cut-off level of 0.15 mg/L in 22
patients (61%). Ten of 16 patients with RV dilation (62.5%)
had increased troponin I levels, while only 4 of 14 patients
(28.6%) with elevated troponin I values had RV diameters
#30 mm. Sixteen patients with normal RV diameter and six
patients with RV dilation had negative troponin I tests. Five
patients had slightly elevated CK values; all of them had
positive lung scans, and four had an elevated RV diameter as
assessed by echocardiography. In four patients with normal
tests at admission, pathologically elevated serum levels were
detected up to 6 h later, suggesting a lag period during
which troponin I did not appear in the peripheral blood.
The clinical data of the study patients are summarized in
Table 2.
Using Pearson chi-square tests, positive troponin I tests
were significantly associated with RV dilatation (p 5
0.009). Although serum D-dimers concentrations above the
cut-off level had a significantly higher sensitivity than
troponin I tests for identifying patients with pulmonary
embolism, D-dimers failed to predict RV dilatation (p 5
0.35). Although study patients with elevated serum levels of
troponin I had a statistically greater prevalence of RV
dilatation, there was no such association between CK-MB
levels and ventricular overload (p . 0.70). Elevated serum
levels of troponin I were found to be associated with atrial
fibrillation (p 5 0.009) and S-waves in lead I and aVL (p 5
0.03) but not with other electrocardiographic changes such
as right axis deviation or RBBB (p . 0.05).
Although study patients with elevated troponin I had
lower levels of arterial partial pressures of O2 (mean 56.6 6
15.7 mm Hg) compared with patients with negative tests
(mean 64.1 6 10.0 mm Hg), this difference was not
statistically significant (p 5 0.11). However, the number of
segmental defects in lung scans was significantly associated
with the results from the troponin I measurements. Patients
with positive troponin I assays had statistically more seg-
mental defects on lung scans than patients with normal
troponin serum levels (p 5 0.0002).
DISCUSSION
Newly developed highly sensitive assays for troponin I
allow the detection of troponin I elevations in acute
pulmonary embolism. Our main observation in this inves-
tigation was that more than one third (39%) of the patients
clinically diagnosed as having acute pulmonary embolism
presented with elevated troponin I serum concentrations.
Furthermore, we demonstrated that in the study sample
positive troponin I tests were significantly associated with
the occurrence of RV dysfunction. In this prospective study
we showed that, in patients with acute pulmonary embo-
lism, the presence of echocardiographic signs of RV dys-
function is statistically related to elevated troponin I con-
centrations in the systemic circulation.
Although troponin I is a well-known diagnostic marker of
myocardial ischemia in unstable angina pectoris resulting from
CHD, no systematic investigation so far has evaluated the
diagnostic usefulness and applicability of newly developed,
highly sensitive troponin I assays for identifying patients at
high risk to develop RV overload in case of pulmonary
embolism (19). In this study the diagnostic significance of the
ACS:180 troponin I values in detecting objective signs of
ischemia of the RV was tested using an easily performable
automated chemiluminescence system based on a two-site
Table 1. Baseline Characteristics of Patient Population
Men (n) 13 (36%)
Age (yrs) 60.8 6 16.1
Women (n) 23 (64%)
Age (yrs) 63.7 6 15.2
Thoracic pain 13 (36%)
Dyspnea 33 (92%)
Syncope 33 (92%)
Cardiogenic shock 3 (8%)
Death during hospital treatment 0 (0%)
Postoperative period 12 (33%)
Malignant tumor 6 (17%)
Deep-vein thrombosis 17 (47%)
Assisted ventilation 2 (6%)
Electrocardiographic changes
S-waves in lead I and aVL 3 (8%)
Right axis deviation 3 (8%)
Atrial fibrillation 4 (11%)
Right bundle branch block 6 (17%)
Right precordial T-wave inversion 10 (28%)
Right ventricular dilation .30 mm
(n 5 36)
16 (44%)
Positive lung scans (n 5 29) 29 (81%)
Pulmonary hypertension (n 5 23) 16 (70%)
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sandwich immunoassay. This newly developed troponin I assay
allows the detection of low concentrations of this marker in the
systemic circulation, presumably because the amount of myo-
cardial damage increases as pulmonary hypertension rises. In
healthy, normal individuals troponin I concentrations are
below the cut-off limit, which is 0.15 mg/L for the ACS:180
analyzer (8).
Positive troponin I results are associated with echocar-
diographic signs of RV dilation. Patients with severe
pulmonary embolism are at a high risk of developing
increased pulmonary vascular resistance, subsequently lead-
ing to RV dilation and hypokinesia (2–7). Echocardiogra-
phy is a well-established and useful tool for distinguishing
fulminant, life-threatening embolism from incidental, clin-
ically unimportant thromboembolism, because it permits
the reliable and rapid noninvasive detection of right heart
pressure overload (3,4,6,7). The presence of troponin levels
above the upper limit of the reference range seems to
represent a clinically important determinant of adverse
myocardial affection. Thus, measuring troponin I provides
additional information for evaluating patients with pulmo-
nary thromboembolism and permits the early identification
of patients at increased risk for hemodynamic deterioration.
Numerous clinical studies have demonstrated that pa-
tients with pulmonary embolism have a poorer prognosis if
they present with increased RV afterload, suggesting that
troponin I measurements may be useful in routine clinical
practice for the early risk assessment of these patients (2–7).
Our data did not allow us to recommend troponin I for the
prediction of unfavorable outcomes in patients presenting
with pulmonary embolisms, because a follow-up investiga-
tion to assess mortality in this study population had not
been performed. However, these data indicate that further
clinical studies to determine the prognostic value of tropo-
nin I assays in this setting are warranted because troponin I,
shown in this investigation to identify patients with RV
dysfunction, may contribute to the prediction of survival.
Segmental defects in lung scans are related to troponin I
elevations. It appeared that major pulmonary embolism, as
judged by numerous segmental defects in lung scans and
Table 2. Clinical Data of the Patient Population
Patient Gender TT RV LS PAP AF SW DVT SH
1 1 0 30 3 19 0 0 0 0
2 2 0 36 3 nd 0 0 0 0
3 2 1 22 2 nd 0 0 0 0
4 2 0 24 4 12 0 0 1 0
5 1 0 27 1 36 0 0 0 0
6 1 0 29 0 nd 0 0 0 0
7 2 0 28 2 nd 0 0 1 0
8 1 1 36 8 nd 0 0 0 0
9 1 1 42 13 60 0 0 1 0
10 2 1 30 10 13 0 0 1 1
11 1 0 20 2 15 0 0 0 0
12 1 1 30 0 60 1 0 0 0
13 1 0 18 2 26 0 0 0 0
14 2 0 29 0 nd 0 0 0 0
15 1 0 26 4 10 0 0 0 0
16 1 0 29 3 51 0 0 0 0
17 2 0 28 6 nd 0 0 1 0
18 1 1 41 12 46 0 0 0 0
19 1 0 47 0 61 0 0 1 0
20 1 1 35 17 35 0 0 1 1
21 2 1 30 2 54 1 0 0 0
22 1 0 23 3 nd 0 0 1 0
23 1 0 24 3 nd 0 0 0 0
24 2 0 31 4 nd 0 0 1 0
25 2 0 24 2 nd 0 0 1 0
26 1 1 31 10 53 1 1 0 0
27 1 1 40 10 41 0 1 0 0
28 1 1 35 5 73 0 0 1 1
29 1 0 31 0 30 0 0 1 0
30 2 1 46 5 37 0 0 1 0
31 2 0 23 2 13 0 0 1 0
32 1 0 50 7 63 0 0 1 0
33 2 1 46 0 18 1 1 0 0
34 1 0 28 2 nd 0 0 0 0
35 1 1 41 10 41 0 0 1 0
36 1 0 32 0 nd 0 0 1 0
AF 5 diagnosis of atrial fibrillation (0 5 neg.; 1 5 pos.); DVT 5 diagnosis of deep venous thrombosis (0 5 neg.; 1 5 pos.); Gender (1 5 female; 2 5 male); LS 5 results
from lung scans (numbers of segmental defects); nd 5 not determined; PAP 5 systolic pulmonary artery pressure (mm Hg); RV 5 echocardiographic dimensions of the right
ventricle (mm); SH 5 diagnosis of shock; SW 5 S-waves in lead I and aVL (0 5 neg.; 1 5 pos.); TT 5 results from troponin I tests (0 5 negative; 1 5 positive).
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echocardiographic signs of RV dysfunction, may be detected
early with the adjunctive knowledge of troponin I values.
Because of the high sensitivity of troponin I for the detection
of minor myocardial damage, above-normal levels of this
cardiac-specific marker may contribute to the early prediction
of hemodynamic instability in individuals diagnosed as having
pulmonary embolism. Our data suggest that immediate tropo-
nin I measurements performed in a routine clinical setting may
help to simplify the risk stratification of patients suffering from
this potential life-threatening disease. The benefit of troponin
I in distinguishing between major and limited courses of
pulmonary embolism argues for the inclusion of troponin I
assays into the routine evaluation of patients with acute
episodes of thromboembolism.
In conclusion, the data from this study demonstrate that
troponin tests are highly sensitive for the early detection of
minor myocardial-cell injury in pulmonary embolism associ-
ated with RV dysfunction. Furthermore, positive troponin I
tests appear to directly reflect the impairment of pulmonary
blood flow as assessed by a significant association with the
number of segmental defects in lung scans. These results are
consistent with the hypothesis that troponin I positivity helps
to identify patients with major pulmonary embolism. Our
study provides evidence that troponin I measurements do not
enable us to distinguish specifically between coronary and
noncoronary causes of chest pain, because, in some patients
presenting with pulmonary embolism, elevated troponin I
concentrations above the normal range are observed as well.
The use of this biochemical marker in addition to established
apparative procedures such as echocardiography, angiography
and lung scanning will extend the diagnostic regimen for an
early identification of patients with RV afterload stress.
Acknowledgments
The authors gratefully acknowledge the skillful technical
assistance of Ina Martetschla¨ger and Irmina Szymczak. We
also thank Bayer Diagnostics (Fernwald, Germany) for
providing us with troponin I assay kits.
Reprint requests and correspondence: Dr. Thomas Meyer,
Center of Internal Medicine, University of Go¨ttingen, Robert-
Koch-Str. 40, D-37075 Go¨ttingen, Germany.
REFERENCES
1. Egermayer P, Town GI, Turner JG, Heaton DC, Mee AL, Beard
MEJ. Usefulness of D-dimer, blood gas, and respiratory rate measure-
ments for excluding pulmonary embolism. Thorax 1998;53:830–4.
2. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism:
clinical outcomes in the International Cooperative Pulmonary Embo-
lism Registry. Lancet 1999;353:1386–9.
3. Kasper W, Konstantinides S, Geibel A, et al. Management strat-
egies and determinants of outcome in acute major pulmonary
embolism. Results of a multicenter registry. J Am Coll Cardiol
1997;30:1165–71.
4. Kasper W, Konstantinides S, Geibel A, Tiede N, Krause T, Just H.
Prognostic significance of right ventricular afterload stress detected by
echocardiography in patients with clinically suspected pulmonary
embolism. Heart 1997;77:346–9.
5. Ketai L, Wiest P, Wolf N, Jones B. Detection of pulmonary emboli
and associated right heart dysfunction by combining ventilation
perfusion lung scanning and xenon vetriculography. Clin Nuc Med
1997;22:817–20.
6. Konstantinides S, Geibel A, Olschewski M, et al. Association between
thrombolytic treatment and the prognosis of hemodynamically stable
patients with major pulmonary embolism. Results of a multicenter
registry. Circulation 1997;96:882–8.
7. Lualdi JC, Goldhaber SZ. Right ventricular dysfunction after acute
pulmonary embolism: pathophysiologic factors, detection, and thera-
peutic implications. Am Heart J 1995;130:1276–82.
8. Adams JE, Bodor GS, Da´vila-Roma´n VG, et al. Cardiac troponin I.
A marker with high specificity for cardiac injury. Circulation 1993;88:
101–6.
9. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific
troponin I levels to predict the risk of mortality in patients with acute
coronary syndromes. N Engl J Med 1996;335:1342–9.
10. Falahati A, Sharkey SW, Christensen D, et al. Implementation of
serum cardiac troponin I as marker for detection of acute myocardial
infarction. Am Heart J 1999;137:332–7.
11. Galvani M, Ottani F, Ferrini D, et al. Prognostic influence of elevated
values of cardiac troponin I in patients with unstable angina. Circu-
lation 1997;95:2053–9.
12. Hamm CW, Goldmann BU, Heeschen C, Kreymann G, Berger J,
Meinertz T. Emergency room triage of patients with acute chest pain
by means of rapid testing for cardiac troponin T or troponin I. N Engl
J Med 1997;337:1648–53.
13. Kontos MC, Jesse RL, Anderson FP, Schmidt KL, Ornato JP, Tatum
JL. Comparison of myocardial perfusion imaging and cardiac troponin
I in patients admitted to the emergency department with chest pain.
Circulation 1999;99:2073–8.
14. Lu¨scher MS, Thygesen K, Ravkilde J, Heickendorff L. Applicability of
cardiac troponin T and I for early risk stratification in unstable
coronary artery disease. Circulation 1997;96:2578–85.
15. Meyer T, Binder L, Graeber T, et al. Superiority of combined
CK-MB and troponin I measurements for the early risk stratification
of unselected patients presenting with acute chest pain. Cardiology
1998;90:286–94.
16. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe
congestive heart failure. Circulation 1997;96:2953–8.
17. Polanczyk CA, Lee TH, Cook EF, et al. Cardiac troponin I as a
predictor of major cardiac events in emergency department patients
with acute chest pain. J Am Coll Cardiol 1998;32:8–14.
18. Katrukha AG, Bereznikova AV, Esakova TV, et al. Troponin I is
released in bloodstream of patients with acute myocardial infarction
not in free form but as complex. Clin Chem 1997;43:1379–85.
19. Pacouret G, Schellenberg F, Hamel E, Charbonnier B, Mouray H.
Troponine I dans l’embolie pulmonaire aigue massive: re´sultats d’une
se´rie prospective. La Presse Me´dicale 1998;27:1627.
1636 Meyer et al. JACC Vol. 36, No. 5, 2000
Troponin I Elevation in Pulmonary Embolism November 1, 2000:1632–6
